IP Library Granted Patent US 11,667,910
Granted Patent B2
US 11,667,910 · App. 17/591,978 · Granted Jun 6, 2023

Method for producing and purifying RNA, comprising at least one step of tangential flow filtration

Inventors: Andreas Funkner (Tübingen, DE); Stefanie Dorner (Tübingen, DE); Stefanie Sewing (Tübingen, DE); Johannes Kamm (Tübingen, DE); Norbert Broghammer (Tübingen, DE); Thomas Ketterer (Gomaringen, DE); Thorsten Mutzke (Reutlingen, DE)
Assignee: CureVac Manufacturing GmbH
C12N15/1017B01D61/145B01D71/12C12P19/34G01N30/02G01N2030/027
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,667,910
App. No.
17/591,978
Granted
Jun 6, 2023
Kind
B2
Abstract

The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).

Claims (30)

1. A method for producing purified RNA, comprising the steps of:

A1) providing plasmid DNA encoding a RNA of 500 to 10000 nucleotides in length;

A2) linearizing the DNA with a restriction endonuclease to produce linearized DNA;

B) transcribing the linearized DNA to yield transcribed RNA, wherein said transcribing is in a solution comprising: nucleoside triphosphates (NTPs); T7 polymerase, spermidine, salts and a HEPES or TRIS buffer; and

C) purifying the transcribed RNA by performing at least one step of tangential flow filtration (TFF) using a TFF membrane cassette, thereby producing purified RNA, wherein the method comprises at least one step of DNA or RNA purification using chromatography.

2. The method of claim 1 , wherein the at least one step of DNA or RNA purification using chromatography comprises using anion exchange chromatography.

3. The method of claim 1 , wherein at least one step of TFF is performed after the chromatography.

4. The method of claim 1 , wherein C) purifying the transcribed RNA comprises at least two steps of TFF.

5. The method of claim 4 , wherein the at least two steps of TFF are both using a TFF membrane cassette.

6. The method of claim 1 , wherein the TFF membrane cassette comprises a cellulose-based TFF membrane.

7. The method of claim 6 , wherein C) purifying the transcribed RNA comprises performing at least one step of TFF with an aqueous salt solution.

8. The method of claim 7 , wherein the aqueous salt solution is a NaCl solution or an organic salt solution.

9. The method of claim 7 , wherein performing at least one step of TFF comprises using a TFF membrane with a molecular weight cutoff of ≤500 kDa.

10. The method of claim 1 , further comprising treating the solution with DNAse after said transcribing.

11. The method of claim 1 , wherein the RNA is a mRNA.

12. The method of claim 9 , wherein the transcribing is in a buffer comprising 0.1 mM to 10 mM spermidine.

13. The method of claim 12 , wherein the method produces purified RNA with a reduced level of spermidine relative to the level of spermidine in step B.

14. The method of claim 11 , wherein the mRNA comprises a modified nucleotide.

15. The method of claim 14 , wherein the modified nucleotide is 1-methyl-pseudouridine.

16. The method of claim 13 , wherein the transcribing is in a buffer comprising a HEPES buffer.

17. The method of claim 13 , wherein performing at least one step of TFF comprises using a TFF membrane with a molecular weight cutoff of about 100 kDa to 300 kDa.

18. The method of claim 13 , wherein the membrane cassette of step C2) has a MWCO of about 300 kDa.

19. The method of claim 13 , wherein the RNA is 500 to 5000 nucleotides in length.

20. The method of claim 19 , wherein the transcribing is in a buffer comprising a cap analog to produce a capped RNA.

21. The method of claim 20 , wherein the capped RNA is a CAP1 capped RNA.

22. The method of claim 21 , wherein the restriction endonuclease is a type II restriction endonuclease.

23. The method of claim 17 , wherein the method further comprises formulating the purified RNA.

24. The method of claim 22 , further comprising a filling step.

25. The method of claim 17 , wherein the TFF membrane cassette comprises a stabilized cellulose-based TFF membrane.

26. The method of claim 23 , wherein formulating the purified RNA comprises complexing the RNA with a cationic compound.

Assignments (1)
CHANGE OF NAME Recorded Nov 12, 2022
From: CUREVAC REAL ESTATE GMBH
To: CUREVAC MANUFACTURING GMBH
Reel/Frame 061932/0502 →
Priority Claims (1)
WO PCT/EP2015/062002 · May 29, 2015 · international
Continuity (3)
Continuation 16934279 · Jul 21, 2020
Continuation 15580092
Related Publication 20220325273A1 · Oct 13, 2022
Cited By (4)
US 12,221,605 US 12,240,873 US 12,385,088 US 12,528,855